 | |
| Clinical data | |
|---|---|
| Trade names | Demovis, Pilomin, others |
| Other names | W-4540; Norethisterone acetate 3-cyclopentyl enol ether; 17α-Ethynyl-19-nortestosterone acetate 3-cyclopentyl enol ether; ENTACP; (17β)-3-(Cyclopentyloxy)-17-ethynylestra-3,5-dien-17-yl acetate |
| Routes of administration | By mouth |
| Drug class | Progestogen;Progestin;Progestogen ester |
| ATC code | |
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| ChEBI | |
| ChEMBL | |
| CompTox Dashboard(EPA) | |
| ECHA InfoCard | 100.019.163 |
| Chemical and physical data | |
| Formula | C27H36O3 |
| Molar mass | 408.582 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Quingestanol acetate, sold under the brand namesDemovis andPilomin among others, is aprogestin medication which was used inbirth control pills but is no longer marketed.[1] It is takenby mouth.[2][3][4]
Quingestanol acetate is a progestin, or asyntheticprogestogen, and hence is anagonist of theprogesterone receptor, thebiological target of progestogens likeprogesterone.[2][3][4] It has weakandrogenic andestrogenic activity and no other importanthormonal activity.[2][3][4] The medication is aprodrug ofnorethisterone in the body, withquingestanol andnorethisterone acetate occurring asintermediates.[5][6]
Quingestanol acetate waspatented in 1963 and was introduced for medical use in 1972.[7][8] It was marketed inItaly.[8]
Quingestanol acetate was used as anoral, once-a-month, orpostcoitalhormonal contraceptive.[2][3][4]
Quingestanol acetate is aprogestogen, and also has weakandrogenic andestrogenic activity.[2][3][4] It is aprodrug ofnorethisterone, with bothquingestanol andnorethisterone acetate serving asintermediates in thetransformation.[5][6] Unlikepenmesterol (methyltestosterone 3-cyclopentyl enol ether) andquinestrol (ethinylestradiol 3-cyclopentyl ether), quingestanol acetate is not stored infat and does not have a prolongedduration of action.[2]
Quingestanol acetate, also known as norethisterone 17β-acetate 3-cyclopentyl enol ether or as 17α-ethynyl-19-nortestosterone 17β-acetate 3-cyclopentyl enol ether (ENTACP), as well as 3-(cyclopentyloxy)-17α-ethynylestra-3,5-dien-17β-yl acetate, is asyntheticestranesteroid and aderivative oftestosterone.[1] It is specifically a derivative of19-nortestosterone and17α-ethynyltestosterone, or ofnorethisterone (17α-ethynyl-19-nortestosterone), in which acyclopentylenol ethergroup has been attached at the C3 position and anacetateester has been attached at the C17β position.[1] Quingestanol acetate is the C17βacetateester ofquingestanol (norethisterone 3-cyclopentyl enol ether).[1]
Quingestanol acetate was patented in 1963[7] and marketed inItaly in 1972.[8][9]
Quingestanol acetate is thegeneric name of the drug and itsINNTooltip International Nonproprietary Name andUSANTooltip United States Adopted Name.[1]
Quingestanol acetate was marketed under the brand names Demovis, Pilomin, Riglovis, and Unovis.[1][7]
Similar androgenic potential is inherent to norethisterone and its prodrugs (norethisterone acetate, ethynodiol diacetate, lynestrenol, norethynodrel, quingestanol).